 |
 | Impact of the use of biologics and their discontinuation on the gut microbiota of psoriasis patients
Penas Steinhardt, Alberto
Ver Cita | Ver Registro | Texto completo (PDF) Penas Steinhardt, Alberto
Impact of the use of biologics and their discontinuation on the gut microbiota of psoriasis patients / Penas Steinhardt, Alberto. [s.l.] : [s.n.], 20190000. 1 pagina. | Registro del documento | | Título: | Impact of the use of biologics and their discontinuation on the gut microbiota of psoriasis patients | | Autor(es): | Penas Steinhardt, Alberto | | Descripción: | Fil: Penas Steinhardt, Alberto. Instituto Universitario de Ciencias de la Salud. Fundación Barceló; Argentina. | | Resumen: | Increasing number of studies have shown that the imbalance of gut microbial populations or dysbiosis may be implicated in psoriasis pathogenesis 1 Psoriasis treatment can shift the abundance of specific taxa however the effect of treatment discontinuation on gut microbiota has not been investigated At the start of the COVID 19 pandemic in March 2020 it was unclear whether patients on biologics were at risk of complications from COVID 19 infection The decision to continue or stop treatment in a group of patients under secukinumab treatment was individualised and agreed with the patient According to Blauvelt et al the median time to loss of PASI 50 after secukinumab withdrawal was 28 weeks so patients were not at increased risk of relapse 2 The aim of this study was to investigate whether there were differences in gut microbiota of psoriasis patients treated with secukinumab (IL 17 A inhibitor compared to controls non treated moderate to severe psoriasis patients and psoriasis patients after 3 months of secukinumab discontinuation discontinuation group | | Descriptores: | | | Contribuidores: | Dei-Cas, Ignacio; Rosso, Ayelen; Giliberto, Florencia | | Fecha: | 20190000 | | Formato: | application/pdf | | Extensión: | 1 pagina | | Idioma: | eng | | Lugar: | 7006287, Argentina (nation) | | Sede: | Buenos Aires | | Carrera: | MEDICINA | | Notas: | Trabajo de investigación publicado |
|
| | Metagenomic analysis of gut microbiota in non‑treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis‑Microbiome Index
Penas Steinhardt, Alberto
Ver Cita | Ver Registro | Texto completo (PDF) Penas Steinhardt, Alberto
Metagenomic analysis of gut microbiota in non‑treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis‑Microbiome Index / Penas Steinhardt, Alberto. [s.l.] : [s.n.], 2020-09-10. 11 paginas. | Registro del documento | | Título: | Metagenomic analysis of gut microbiota in non‑treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis‑Microbiome Index | | Autor(es): | Penas Steinhardt, Alberto | | Descripción: | Fil: Penas Steinhardt, Alberto. Instituto Universitario de Ciencias de la Salud – Fundación Barceló. Secretaria de Ciencia y Tecnologia; Argentina. | | Resumen: | Psoriasis is an immune-mediated skin disorder. Imbalance of gut microbial populations has been implicated in many diseases. We aimed to investigate whether there were differences in gut microbiota in psoriasis patients vs non-psoriasis controls and between psoriasis severity groups. 55 psoriasis patients and 27 controls were included. V3–V4 regions of the 16S rRNA gene of fecal samples were analyzed using Illumina MiSeq. Bioinformatic analysis was performed. We found changes in gut microbiome composition depending on their psoriasis status as determined by weighted unifrac (p < 0.05), in particular an increase in Firmicutes and depletion of Bacteroidetes in psoriasis patients. Additionally, the Faecalibacterium and Blautia genus were higher in psoriasis patients while Bacteroides and Paraprevotella in non-psoriasis controls (p < 0.05, LDA score > 2). Moderate-to-severe psoriasis patients had lower biodiversity than mild psoriatic patients (p = 0.049). No differences for beta-diversity were found. We developed a Psoriasis-Microbiota Index (PMI), which discriminated among psoriasis patients and controls with sensitivity: 0.78 and specificity: 0.79. Furthermore, we performed a meta-analysis with published data to validate this index. We demonstrated gut dysbiosis in psoriasis patients, suggesting a role in psoriasis pathophysiology. Furthermore, we developed a PMI with the potential to discriminate between psoriasis patients and controls across different populations, which could be used as a biomarker in the clinical practice. | | Descriptores: | | | Fecha: | 2020-09-10 | | Formato: | application/pdf | | Extensión: | 11 paginas | | Idioma: | eng | | Lugar: | 7006287, Buenos Aires (inhabited place) | | Sede: | Buenos Aires | | Carrera: | MEDICINA | | Notas: | Proyecto de investigación |
|
|
